RU99101057A - CONNECTIONS OF THE ANDROGEN RECEPTOR MODULATOR AND METHODS - Google Patents
CONNECTIONS OF THE ANDROGEN RECEPTOR MODULATOR AND METHODSInfo
- Publication number
- RU99101057A RU99101057A RU99101057/04A RU99101057A RU99101057A RU 99101057 A RU99101057 A RU 99101057A RU 99101057/04 A RU99101057/04 A RU 99101057/04A RU 99101057 A RU99101057 A RU 99101057A RU 99101057 A RU99101057 A RU 99101057A
- Authority
- RU
- Russia
- Prior art keywords
- pyridone
- quinoline
- trifluoromethyl
- tetrahydro
- hydrogen
- Prior art date
Links
- 239000000849 selective androgen receptor modulator Substances 0.000 title 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 27
- 229910052739 hydrogen Inorganic materials 0.000 claims 24
- 239000001257 hydrogen Substances 0.000 claims 24
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 claims 24
- 150000001875 compounds Chemical class 0.000 claims 20
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 125000001072 heteroaryl group Chemical group 0.000 claims 13
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 12
- 125000005002 aryl methyl group Chemical group 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 11
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 9
- 108010080146 androgen receptors Proteins 0.000 claims 8
- 102000001307 androgen receptors Human genes 0.000 claims 7
- 230000000051 modifying Effects 0.000 claims 7
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 230000037396 body weight Effects 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 4
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 4
- 206010000496 Acne Diseases 0.000 claims 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 206010020112 Hirsutism Diseases 0.000 claims 3
- 229940088597 Hormone Drugs 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 3
- 239000003263 anabolic agent Substances 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000001419 dependent Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 230000011132 hemopoiesis Effects 0.000 claims 3
- 239000005556 hormone Substances 0.000 claims 3
- 238000002657 hormone replacement therapy Methods 0.000 claims 3
- 230000001404 mediated Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 230000000638 stimulation Effects 0.000 claims 3
- 206010068168 Androgenetic alopecia Diseases 0.000 claims 2
- 206010058359 Hypogonadism Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 102100007495 AR Human genes 0.000 claims 1
- 102000007399 Nuclear hormone receptors Human genes 0.000 claims 1
- 125000005024 alkenyl aryl group Chemical group 0.000 claims 1
- 125000005025 alkynylaryl group Chemical group 0.000 claims 1
- 201000004384 alopecia Diseases 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 239000003098 androgen Substances 0.000 claims 1
- 239000003936 androgen receptor antagonist Substances 0.000 claims 1
- 125000005418 aryl aryl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000004031 partial agonist Substances 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims 1
Claims (20)
где R1 представляет собой водород, F, Cl, Br, I, NO2, OR20, NR21R22, SR20, C1-C4алкил или представляет собой возможно замещенный аллил, арилметил, алкинил, алкенил, арил или гетероарил, где R21 представляет собой водород, C1-C6алкил или перфторалкил, арил, гетероарил, возможно замещенный аллил или арилметил, SO2R23 или S(O)R23, где R23 представляет собой водород, C1-C6алкил или перфторалкил, арил, гетероарил, возможно замещенный аллил или арилметил, R20 представляет собой водород, C1-C6алкил или перфторалкил, арил, гетероарил, возможно замещенный аллил или арилметил, а R22 представляет собой водород, C1-C4алкил или перфторалкил, арил, гетероарил, возможно замещенный аллил или арилметил, OR20 или NHR21;
R2 представляет собой водород, F, Br, Cl, C1-C4-алкил или пергалогеноалкил, арил, гетероарил, CF3, CF2H, CFH2, CF2OR20, CH2OR20 или OR20, где R20 имеет значение, приведенное выше;
R3 представляет собой водород, C1-C4алкил, F, Cl Br, I, OR20, NR21R22 или SR20, где R20 - R22 имеют значения, приведенные выше;
R4 и R5 каждый независимо представляет собой водород C1-C4алкил или перфторалкил, гетероарил, возможно замещенный аллил, арилметил, алкинил или алкенил или арил, возможно замещенный водородом, F, Cl Br, OR20 или NR21R22, или R4 и R5, взятые вместе, могут образовывать трех- - семи-членное кольцо, возможно замещенное водородом, F, Cl, Br, OR20 или NR21R22, где R20 - R22 имеют значения, приведенные выше;
R6 и R7 каждый независимо представляет собой водород, C1-C4алкил или перфторалкил, гетероарил, возможно замещенный аллил, арилметил, алкинил или алкенил или арил, возможно замещенный водородом, F, Cl, Br, OR20 или NR21R22, или R6 и R7, взятые вместе, могут образовывать трех- - семи-членное кольцо, возможно замещенное водородом, F, Cl, Br, OR20 или NR21R22, где R20 - R22 имеют значения, определенные выше;
R8 представляет собой C1-C12алкил или перфторалкил, гидроксиметил, арил, гетероарил или возможно замещенный аллил, арилметил, алкинил или алкенил;
R9 - R18 каждый независимо представляет собой водород, C1-C4алкил или перфторалкил, гетероарил, возможно замещенный аллил, арилметил, алкинил или арил, возможно замещенный водородом, F, Cl, Br, OR20 или NR21R22, или любые два из R9 - R18, взятые вместе, могут образовывать трех- - семичленное кольцо, возможно замещенное водородом, F, Cl, Br, OR20 или NR21R22, где R20 - R22 имеют значения, приведенные выше;
R19 представляет собой F, NO2 или SR20, где R20 имеет значение, приведенное выше;
R24 представляет собой водород, C1-C4алкил, F, Cl, Br, OR20, NR21R22 или SR20, где R20 - R22 имеют значения, приведенные выше;
R25 представляет собой водород, C1-C12алкил или перфторалкил, гидроксиметил, арил, гетероарил или возможно замещенный аллил, арилметил, алкинил или алкенил, или R25 и R8, взятые вместе, могут образовывать трех- - семичленное кольцо, возможно замещенное водородом, F, Cl, Br, OR20 или NR21R22, где R20 - R22 имеют значения, приведенные выше;
R26 является водородом, C1-C6алкилом или перфторалкилом, NO2, OR20, C(O)R20, C(O)OR20, C(O)NR21R22 или возможно замещенным арилом, гетероарилом, аллилом или арилметилом, где R20 - R22 имеют значения, приведенные выше;
R27 и R28 каждый независимо представляет собой водород, F, Cl, Br, I, OR20, NR21R22, C1-C4алкил или перфторалкил, гетероарил, возможно замещенный аллил, арилметил, алкинил или алкенил или арил, возможно замещенный водородом, F, Cl, Br, OR20 или NR21R22, или R27 и R28, взятые вместе, могут образовывать трех- - семичленное кольцо, возможно замещенное водородом, F, Cl, Br, OR20 или NR21R22, где R20 - R22 имеют значения, приведенные выше;
m равно 0 или1;
n равно 0 или 1; и
o равно 0 или 1; Y является O или S;
Z представляет собой O, S, NH, NR22 или NCOR22, где R22 имеет значение, представленное выше; и
любые два из R4 - R8, R25 и R28, взятые вместе, могут образовывать трех- - семичленное кольцо, возможно замещенное водородом, F, Cl, Br, OR20 или NR21R22, где R20 - R22 имеют значения, приведенные выше.1. The compound having the formula:
where R 1 represents hydrogen, F, Cl, Br, I, NO 2 , OR 20 , NR 21 R 22 , SR 20 , C 1 -C 4 alkyl or is a possibly substituted allyl, arylmethyl, alkynyl, alkenyl, aryl or heteroaryl, where R 21 represents hydrogen, C 1 -C 6 alkyl or perfluoroalkyl, aryl, heteroaryl, possibly substituted allyl or arylmethyl, SO 2 R 23 or S (O) R 23 , where R 23 represents hydrogen, C 1 - C 6 alkyl or perfluoroalkyl, aryl, heteroaryl, possibly substituted allyl or arylmethyl, R 20 is hydrogen, C 1 -C 6 alkyl or perfluoroalkyl, aryl, heteroaryl, possibly substituted allyl or aryl methyl, and R 22 is hydrogen, C 1 -C 4 alkyl or perfluoroalkyl, aryl, heteroaryl, optionally substituted allyl or arylmethyl, OR 20 or NHR 21 ;
R 2 is hydrogen, F, Br, Cl, C 1 -C 4 -alkyl or perhaloalkyl, aryl, heteroaryl, CF 3 , CF 2 H, CFH 2 , CF 2 OR 20 , CH 2 OR 20 or OR 20 , where R 20 has the meaning given above;
R 3 is hydrogen, C 1 -C 4 alkyl, F, Cl Br, I, OR 20 , NR 21 R 22 or SR 20 , where R 20 - R 22 are as defined above;
R 4 and R 5 each independently represents hydrogen C 1 -C 4 alkyl or perfluoroalkyl, heteroaryl, possibly substituted allyl, arylmethyl, alkynyl or alkenyl or aryl, possibly substituted by hydrogen, F, Cl Br, OR 20 or NR 21 R 22 , or R 4 and R 5 taken together may form a three- to seven-membered ring, possibly substituted by hydrogen, F, Cl, Br, OR 20 or NR 21 R 22 , where R 20 - R 22 have the meanings given above;
R 6 and R 7 each independently represents hydrogen, C 1 -C 4 alkyl or perfluoroalkyl, heteroaryl, possibly substituted allyl, arylmethyl, alkynyl or alkenyl or aryl, possibly substituted by hydrogen, F, Cl, Br, OR 20 or NR 21 R 22 , or R 6 and R 7 , taken together, can form a three- to seven-membered ring, possibly substituted by hydrogen, F, Cl, Br, OR 20 or NR 21 R 22 , where R 20 - R 22 have the meanings specified above;
R 8 is C 1 -C 12 alkyl or perfluoroalkyl, hydroxymethyl, aryl, heteroaryl or optionally substituted allyl, arylmethyl, alkynyl or alkenyl;
R 9 - R 18 each independently represents hydrogen, C 1 -C 4 alkyl or perfluoroalkyl, heteroaryl, possibly substituted allyl, arylmethyl, alkynyl or aryl, possibly substituted with hydrogen, F, Cl, Br, OR 20 or NR 21 R 22 , or any two of R 9 - R 18 taken together may form a three- to seven-membered ring, possibly substituted by hydrogen, F, Cl, Br, OR 20 or NR 21 R 22 , where R 20 - R 22 have the meanings given above ;
R 19 is F, NO 2 or SR 20 , where R 20 is as defined above;
R 24 is hydrogen, C 1 -C 4 alkyl, F, Cl, Br, OR 20 , NR 21 R 22, or SR 20 , where R 20 - R 22 are as defined above;
R 25 is hydrogen, C 1 -C 12 alkyl or perfluoroalkyl, hydroxymethyl, aryl, heteroaryl or optionally substituted allyl, arylmethyl, alkynyl or alkenyl, or R 25 and R 8 taken together can form a three- to seven-membered ring, possibly substituted with hydrogen, F, Cl, Br, OR 20 or NR 21 R 22 , where R 20 - R 22 have the meanings given above;
R 26 is hydrogen, C 1 -C 6 alkyl or perfluoroalkyl, NO 2 , OR 20 , C (O) R 20 , C (O) OR 20 , C (O) NR 21 R 22 or possibly substituted aryl, heteroaryl, allyl or arylmethyl, where R 20 - R 22 have the meanings given above;
R 27 and R 28 each independently represents hydrogen, F, Cl, Br, I, OR 20 , NR 21 R 22 , C 1 -C 4 alkyl or perfluoroalkyl, heteroaryl, possibly substituted allyl, arylmethyl, alkynyl or alkenyl or aryl, possibly substituted by hydrogen, F, Cl, Br, OR 20 or NR 21 R 22 , or R 27 and R 28 , taken together, can form a three- to seven-membered ring, possibly substituted by hydrogen, F, Cl, Br, OR 20 or NR 21 R 22 , where R 20 - R 22 have the meanings given above;
m is 0 or 1;
n is 0 or 1; and
o is 0 or 1; Y is O or S;
Z is O, S, NH, NR 22 or NCOR 22 , where R 22 is as defined above; and
any two of R 4 - R 8 , R 25 and R 28 , taken together, can form a three - seven-membered ring, possibly substituted by hydrogen, F, Cl, Br, OR 20 or NR 21 R 22 , where R 20 - R 22 have the meanings given above.
(R/S)-6,7,7а,11-тетрагидро-7а-метил-4-трифторметил-2-пиридоно[5,6g]пирролидино[1,5-а]хинолина;
(R/S)-3-фтор-6,7,7а, 11-тетрагидро-7а-метил-4-трифторметил-2-пиридоно[5,6-g]пирролидино[1,2-а-]хинолина;
(R/S)-6,7,7а,11-тетрагидро-1,7а-диметил-4-трифторметил-2-пиридоно[5,6-g] пирролидино[1,2-а-]хинолина;
(R/S)-3-фтор-6,7,7а, 11-тетрагидро-1,7а-диметил-4-трифторметил-2-пиридоно[5,6-g]пирролидино[1,2-а-]хинолина;
11-(трифторметил)-9-пиридоно[6,5-i]хулолидина;
8-метил-11-(трифторметил)-9-пиридоно[6,5-i]хулолидина;
7-фтор-1,2,3,4-тетрагидро-2,2-диметил-6-трифторметил-8-пиридоно[5,6-g] хинолина;
6-дифторметил-7-фтор-1,2,3,4-тетрагидро-2,2-диметил-8-пиридоно[5,6-g] хинолина;
7-фтор-1,2,3,4-тетрагидро-2,2,9-триметил-6-трифторметил-8-пиридоно[5,6-g]хинолина;
6-дифторметил-7-фтор-1,2,3,4-тетрагидро-2,2,9-триметил-8-пиридоно-[5,6-g]хинолина;
7-фтор-1,2,3,4-тетрагидро-1,2,2,9-тетраметил-6-трифторметил-8-пиридоно-[5,6-g]хинолина;
6-дифторметил-7-фтор-1,2,3,4-тетрагидро-1,2,2,9-тетраметил-8-пиридоно[5,6-g]хинолина;
7-фтор-1,2-дигидро-2,2,4-триметил-6-трифторметил-8-пиридоно[5,6-g]хинолина;
7-фтор-1,2,3,4-тетрагидро-2,2,4-триметил-6-трифторметил-8-пиридоно[5,6-g]хинолина;
1,10-[1,3-дигидро-3-оксо-(2,1-изоксазолил)] -1,2,3,4-тетрагидро-2,2,4,10-тетраметил-6-трифторметил-6-трифторметил-8-пиридоно[5,6-g]хинолина;
7-фтор-1,2-дигидро-2,2,4,10-тетраметил-6-трифторметил-8-пиридоно[5,6-g] хинолина;
7-фтор-1,2,3,4-тетрагидро-2,2,4,10-тетраметил-6-трифторметил-8-пиридоно[5,6-g]хинолина;
7-фтор-1,2,3,4-тетрагидро-2,2,4,10-пентаметил-6-трифторметил-8-пиридоно[5,6-g]хинолина;
7-фтор-1,2,3,4-тетрагидро-1,2,2,4,10-пентаметил-6-трифторметил-8-пиридоно[5,6-g]хинолина;
1,2,3,4-тетрагидро-1-гидрокси-2,2-диметил-6-трифторметил-8-пиридоно[5,6-g]хинолина;
1,2,3,4-тетрагидро-1-гидрокси-2,2,9-триметил-6-трифторметил-8-пиридоно[5,6-g]хинолина;
2,2-диэтил-7-фтор-1,2,3,4-тетрагидро-6-трифторметил-8-пиридоно[5,6-g] хинолина;
(R/S)-4-этил-1-формил-1,2,3,4-тетрагидро-6-(трифторметил)-8-пиридоно[5,6-g]хинолина;
(R/S)-4-этил-1,2,3,4-тетрагидро-1-(трифторацетил)-6-(трифторметил)-8-пиридоно[5,6-g]хинолина;
(R/S)-1-ацетил-4-этил-1,2,3,4-тетрагидро-6-(трифторметил)-8-пиридоно[5,6-g]хинолина;
(R/S)-4-этил-1,2,3,4-тетрагидро-10-нитро-6-(трифторметил)-8-пиридоно[5,6-g]хинолина;
1,2,3,4-тетрагидро-2,2-диметил-10-нитро-6-(трифторметил)-8-пиридоно[5,6-g]хинолина;
1,2,3,4-тетрагидро-2,2-диметил-7,10-динитро-6-(трифторметил)-8-пиридоно[5,6-g]хинолина; и
(R/S)-4-этил-1,2,3,4-тетрагидро-1-нитро-6-(трифторметил)-8- пиридоно[5,6-g]хинолин.6. The compound according to claim 2, selected from the group consisting of
(R / S) -6,7,7a, 11-tetrahydro-7a-methyl-4-trifluoromethyl-2-pyridone [5.6g] pyrrolidino [1,5-a] quinoline;
(R / S) -3-fluoro-6,7,7a, 11-tetrahydro-7a-methyl-4-trifluoromethyl-2-pyridone [5,6-g] pyrrolidino [1,2-a-] quinoline;
(R / S) -6,7,7a, 11-tetrahydro-1,7a-dimethyl-4-trifluoromethyl-2-pyridone [5,6-g] pyrrolidino [1,2-a-] quinoline;
(R / S) -3-fluoro-6,7,7a, 11-tetrahydro-1,7a-dimethyl-4-trifluoromethyl-2-pyridone [5,6-g] pyrrolidino [1,2-a-] quinoline ;
11- (trifluoromethyl) -9-pyridone [6,5-i] chulolidine;
8-methyl-11- (trifluoromethyl) -9-pyridone [6,5-i] chulolidine;
7-fluoro-1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridone [5,6-g] quinoline;
6-difluoromethyl-7-fluoro-1,2,3,4-tetrahydro-2,2-dimethyl-8-pyridone [5,6-g] quinoline;
7-fluoro-1,2,3,4-tetrahydro-2,2,9-trimethyl-6-trifluoromethyl-8-pyridone [5,6-g] quinoline;
6-difluoromethyl-7-fluoro-1,2,3,4-tetrahydro-2,2,9-trimethyl-8-pyridone- [5,6-g] quinoline;
7-fluoro-1,2,3,4-tetrahydro-1,2,2,9-tetramethyl-6-trifluoromethyl-8-pyridone- [5,6-g] quinoline;
6-difluoromethyl-7-fluoro-1,2,3,4-tetrahydro-1,2,2,9-tetramethyl-8-pyridone [5,6-g] quinoline;
7-fluoro-1,2-dihydro-2,2,4-trimethyl-6-trifluoromethyl-8-pyridone [5,6-g] quinoline;
7-fluoro-1,2,3,4-tetrahydro-2,2,4-trimethyl-6-trifluoromethyl-8-pyridone [5,6-g] quinoline;
1,10- [1,3-dihydro-3-oxo- (2,1-isoxazolyl)] -1,2,3,4-tetrahydro-2,2,4,10-tetramethyl-6-trifluoromethyl-6- trifluoromethyl-8-pyridone [5,6-g] quinoline;
7-fluoro-1,2-dihydro-2,2,4,10-tetramethyl-6-trifluoromethyl-8-pyridone [5,6-g] quinoline;
7-fluoro-1,2,3,4-tetrahydro-2,2,4,10-tetramethyl-6-trifluoromethyl-8-pyridone [5,6-g] quinoline;
7-fluoro-1,2,3,4-tetrahydro-2,2,4,10-pentamethyl-6-trifluoromethyl-8-pyridone [5,6-g] quinoline;
7-fluoro-1,2,3,4-tetrahydro-1,2,2,4,10-pentamethyl-6-trifluoromethyl-8-pyridone [5,6-g] quinoline;
1,2,3,4-tetrahydro-1-hydroxy-2,2-dimethyl-6-trifluoromethyl-8-pyridone [5,6-g] quinoline;
1,2,3,4-tetrahydro-1-hydroxy-2,2,9-trimethyl-6-trifluoromethyl-8-pyridone [5,6-g] quinoline;
2,2-diethyl-7-fluoro-1,2,3,4-tetrahydro-6-trifluoromethyl-8-pyridone [5,6-g] quinoline;
(R / S) -4-ethyl-1-formyl-1,2,3,4-tetrahydro-6- (trifluoromethyl) -8-pyridone [5,6-g] quinoline;
(R / S) -4-ethyl-1,2,3,4-tetrahydro-1- (trifluoroacetyl) -6- (trifluoromethyl) -8-pyridone [5,6-g] quinoline;
(R / S) -1-acetyl-4-ethyl-1,2,3,4-tetrahydro-6- (trifluoromethyl) -8-pyridone [5,6-g] quinoline;
(R / S) -4-ethyl-1,2,3,4-tetrahydro-10-nitro-6- (trifluoromethyl) -8-pyridone [5,6-g] quinoline;
1,2,3,4-tetrahydro-2,2-dimethyl-10-nitro-6- (trifluoromethyl) -8-pyridone [5,6-g] quinoline;
1,2,3,4-tetrahydro-2,2-dimethyl-7,10-dinitro-6- (trifluoromethyl) -8-pyridone [5,6-g] quinoline; and
(R / S) -4-ethyl-1,2,3,4-tetrahydro-1-nitro-6- (trifluoromethyl) -8-pyridone [5,6-g] quinoline.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2199796P | 1996-06-27 | 1996-06-27 | |
US60/021,997 | 1996-06-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU99101057A true RU99101057A (en) | 2001-04-10 |
RU2214412C2 RU2214412C2 (en) | 2003-10-20 |
Family
ID=21807289
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU99101057/04A RU2214412C2 (en) | 1996-06-27 | 1997-06-26 | Derivatives of 8-pyridono[5,6-g]quinoline, pharmaceutical composition and method for control with their using |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0918774B9 (en) |
JP (1) | JP2000513362A (en) |
AT (1) | ATE209207T1 (en) |
AU (1) | AU728178B2 (en) |
BR (1) | BR9710988A (en) |
DE (1) | DE69709752T2 (en) |
DK (1) | DK0918774T3 (en) |
ES (1) | ES2168650T3 (en) |
NO (1) | NO311645B1 (en) |
PT (1) | PT918774E (en) |
RU (1) | RU2214412C2 (en) |
WO (1) | WO1997049709A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7705182B2 (en) | 2002-02-28 | 2010-04-27 | University Of Tennessee Research Foundation | Multi-substituted selective androgen receptor modulators and methods of use thereof |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6826407B1 (en) | 1999-03-29 | 2004-11-30 | Richard J. Helferich | System and method for integrating audio and visual messaging |
US6253061B1 (en) | 1997-09-19 | 2001-06-26 | Richard J. Helferich | Systems and methods for delivering information to a transmitting and receiving device |
US6636733B1 (en) | 1997-09-19 | 2003-10-21 | Thompson Trust | Wireless messaging method |
US7003304B1 (en) | 1997-09-19 | 2006-02-21 | Thompson Investment Group, Llc | Paging transceivers and methods for selectively retrieving messages |
US6983138B1 (en) | 1997-12-12 | 2006-01-03 | Richard J. Helferich | User interface for message access |
US6472415B1 (en) * | 1998-12-18 | 2002-10-29 | Biophysica, Inc. | Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes |
EP1212322A2 (en) * | 1999-08-27 | 2002-06-12 | Ligand Pharmaceuticals Incorporated | 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators |
TR200200507T2 (en) * | 1999-08-27 | 2002-10-21 | Ligand Pharmaceuticals Inc | Androgen receptor modulator compounds and methods |
US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
PE20010647A1 (en) | 1999-09-14 | 2001-06-23 | Lilly Co Eli | RETINOID X RECEPTOR MODULATORS (RXR) WITH IMPROVED PHARMACOLOGICAL PROFILE |
CA2386095A1 (en) | 1999-09-30 | 2001-04-05 | Hollis-Eden Pharmaceuticals, Inc. | Therapeutic treatment of androgen receptor driven conditions |
US20030175817A1 (en) * | 2000-02-10 | 2003-09-18 | Kyoji Ikeda | Method of screening for antiandrogen agent |
WO2002000653A2 (en) * | 2000-06-28 | 2002-01-03 | Bristol-Myers Squibb Company | Fused cyclic compounds as modulators of nuclear hormone receptor function |
AU2001267904A1 (en) | 2000-06-30 | 2002-01-14 | Chugai Seiyaku Kabushiki Kaisha | Novel antiandrogenic agent |
ATE318822T1 (en) * | 2000-09-19 | 2006-03-15 | Bristol Myers Squibb Co | CONDENSED HETEROCYCLIC SUCCINIMIDE DERIVATIVES AND THEIR ANALOGS, MODULATORS OF THE CORE HORMONE RECEPTOR FUNCTIONS |
US7214690B2 (en) | 2001-02-23 | 2007-05-08 | Ligand Pharmaceuticals Incorporated | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods |
US7026484B2 (en) | 2001-02-23 | 2006-04-11 | Ligand Pharmaceuticals Incorporated | Tricyclic androgen receptor modulator compounds and methods |
AU2002340256B2 (en) * | 2001-10-19 | 2007-04-05 | Merck Sharp & Dohme Corp. | Androgen receptor modulators and methods of use thereof |
US20050101657A1 (en) * | 2001-12-28 | 2005-05-12 | Takeda Chemical Industries Ltd. | Androgen receptor antagonists |
CA2484340C (en) * | 2002-04-26 | 2011-05-03 | Ortho-Mcneil Pharmaceutical, Inc. | 2-(quinolonyl)-fused heterocycles as androgen receptor modulators |
US7405234B2 (en) | 2002-05-17 | 2008-07-29 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
DE20301728U1 (en) | 2002-10-11 | 2004-03-11 | Ligand Pharmaceuticals, Inc., San Diego | 5-substituted-7,9-difluoro-5H-chromeno (3,4-f) quinoline compounds as selective progesterone receptor modulator compounds |
EP1567487A4 (en) | 2002-11-15 | 2005-11-16 | Bristol Myers Squibb Co | Open chain prolyl urea-related modulators of androgen receptor function |
WO2004065379A1 (en) * | 2003-01-17 | 2004-08-05 | Warner-Lambert Company Llc | Androgen receptor antagonists |
MXPA06001751A (en) | 2003-08-22 | 2006-05-12 | Ligand Pharm Inc | 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds. |
US7256208B2 (en) | 2003-11-13 | 2007-08-14 | Bristol-Myers Squibb Company | Monocyclic N-Aryl hydantoin modulators of androgen receptor function |
US7820702B2 (en) | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
US7696241B2 (en) | 2004-03-04 | 2010-04-13 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
US7388027B2 (en) | 2004-03-04 | 2008-06-17 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
US7625923B2 (en) | 2004-03-04 | 2009-12-01 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
US8519158B2 (en) | 2004-03-12 | 2013-08-27 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
AU2007212191B2 (en) * | 2006-02-10 | 2011-12-22 | Janssen Pharmaceutica N.V. | Novel imidazolopyrazole derivatives useful as selective androgen receptor modulators |
US8268872B2 (en) | 2008-02-22 | 2012-09-18 | Radius Health, Inc. | Selective androgen receptor modulators |
MX2010009162A (en) | 2008-02-22 | 2010-12-21 | Radius Health Inc | Selective androgen receptor modulators. |
EP2130831A1 (en) | 2008-06-06 | 2009-12-09 | InterMed Discovery GmbH | CDC25 inhibitors |
AU2010242339B2 (en) * | 2009-04-30 | 2015-10-01 | Nissan Chemical Industries, Ltd. | Novel crystal forms of tricyclic benzopyran compound and processes for producing same |
CA2788907A1 (en) | 2010-02-04 | 2011-08-11 | Radius Health, Inc. | Selective androgen receptor modulators |
EP3106159A1 (en) | 2010-05-12 | 2016-12-21 | Radius Health, Inc. | Therapeutic regimens |
US8642632B2 (en) | 2010-07-02 | 2014-02-04 | Radius Health, Inc. | Selective androgen receptor modulators |
US9133182B2 (en) | 2010-09-28 | 2015-09-15 | Radius Health, Inc. | Selective androgen receptor modulators |
MX356514B (en) | 2011-01-20 | 2018-05-30 | Univ Texas | Mri markers, delivery and extraction systems, and methods of manufacture and use thereof. |
CA2943611A1 (en) | 2014-03-28 | 2015-10-01 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
RU2022108295A (en) | 2016-06-22 | 2022-04-06 | Эллипсес Фарма Лтд | TREATMENT METHODS FOR AR+ BREAST CANCER |
CN106397317B (en) * | 2016-09-26 | 2019-03-22 | 天津师范大学 | 1,2,3,4- 3,4-tetrahydroquinoline compounds and its synthetic method and application |
CN106565723B (en) * | 2016-11-04 | 2019-08-27 | 江苏师范大学 | A kind of preparation method of furopyridine, benzo pyridines derivative compound |
KR102557321B1 (en) | 2017-01-05 | 2023-07-18 | 래디어스 파마슈티컬스, 인코포레이티드 | Polymorphic forms of rad1901-2hcl |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0485392B1 (en) * | 1989-07-07 | 1998-09-09 | Endorecherche Inc. | Androgen derivatives for use in the inhibition of sex steroid activity |
US5677336A (en) * | 1993-10-21 | 1997-10-14 | Ligand Pharmaceuticals Incorporated | Non-steroid androgen receptor antagonist compounds and methods |
ATE252560T1 (en) * | 1994-12-22 | 2003-11-15 | Ligand Pharm Inc | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS |
-
1997
- 1997-06-26 JP JP10503562A patent/JP2000513362A/en not_active Ceased
- 1997-06-26 PT PT97931460T patent/PT918774E/en unknown
- 1997-06-26 DE DE69709752T patent/DE69709752T2/en not_active Expired - Fee Related
- 1997-06-26 AT AT97931460T patent/ATE209207T1/en not_active IP Right Cessation
- 1997-06-26 DK DK97931460T patent/DK0918774T3/en active
- 1997-06-26 RU RU99101057/04A patent/RU2214412C2/en not_active IP Right Cessation
- 1997-06-26 WO PCT/US1997/011222 patent/WO1997049709A1/en active IP Right Grant
- 1997-06-26 ES ES97931460T patent/ES2168650T3/en not_active Expired - Lifetime
- 1997-06-26 AU AU35084/97A patent/AU728178B2/en not_active Ceased
- 1997-06-26 BR BR9710988-6A patent/BR9710988A/en not_active IP Right Cessation
- 1997-06-26 EP EP97931460A patent/EP0918774B9/en not_active Expired - Lifetime
-
1998
- 1998-12-23 NO NO19986100A patent/NO311645B1/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7705182B2 (en) | 2002-02-28 | 2010-04-27 | University Of Tennessee Research Foundation | Multi-substituted selective androgen receptor modulators and methods of use thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU99101057A (en) | CONNECTIONS OF THE ANDROGEN RECEPTOR MODULATOR AND METHODS | |
RU2214412C2 (en) | Derivatives of 8-pyridono[5,6-g]quinoline, pharmaceutical composition and method for control with their using | |
US6121278A (en) | Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity | |
KR0178808B1 (en) | Camptothecin analogs as potent inhibitors of human colorectal cancer | |
RU2215746C2 (en) | Heterocyclic derivatives of glycyl-beta-alanine as antagonists of vitronectin | |
US20020160984A1 (en) | Fused tricyclic compounds, methods and compositions for inhibiting parp activity | |
US6380193B1 (en) | Fused tricyclic compounds, methods and compositions for inhibiting PARP activity | |
JP2002512637A (en) | Oxo-substituted compounds, production methods and compositions, and methods for inhibiting PARP activity | |
RU99121331A (en) | 1,8-ANNELATED QUINOLINON DERIVATIVES, SUBSTITUTED WITH N-OR C-BINDED IMIDAZOLES, INHIBITING PHARNESILTRANSFERASE | |
ES2103479T3 (en) | ANILIDA DERIVATIVES. | |
RU95108244A (en) | Arylidene and heteroarylideneoxinedole derivatives and process for preparation thereof, drug based thereon, and process for preparation thereof | |
JP2008538546A (en) | Heterocyclic N-oxides as hypoxia selective protein kinase inhibitors | |
AU2004253694A1 (en) | Novel pyrrolodihydroisoquinolines useful in the treatment of cancer | |
WO1999011644A1 (en) | Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity | |
EP0992240A1 (en) | Therapeutic agent for erection failure | |
JPH02501929A (en) | medical use | |
RU2018140732A (en) | Newly substituted imidazopyridine compounds as indolamine-2,3-dioxygenase and / or tryptophan-2,3-dioxygenase inhibitors | |
JPH09510695A (en) | 8-Aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and their use as antagonists to the glycine / NMDA receptor | |
RU2001121160A (en) | The use of pyridazino [4,5-b] indole-1-acetamide derivatives for the preparation of drugs for the treatment of diseases associated with peripheral-type benzodiazepine receptor dysfunction | |
JP2003506378A (en) | Camptothecin aromatic ester and cancer treatment method | |
US20040254372A1 (en) | Compounds, derivatives, compositions, preparation and uses | |
KR950702563A (en) | TETRACYCLIC COMPOUNDS PROCESS AND INTERMEDIATES FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOUR AGENTS | |
KR20050053613A (en) | Antitumoral analogs of lamellarins | |
BG103684A (en) | DERIVATIVES OF 2,3-DIHYDROFLUORO[3,2-b]PYRIDIN, METHOD FOR THEIR PREPARATION AND APPLICATION IN THERAPY | |
ES2123517T3 (en) | PREPARATION METHOD OF CERTAIN PYRANO (3 ', 4': 6,7) INDOLIZINO (1,2-B) QUINOLINONAS. |